Mitotane Lysodren 500mg: Orphan-Drug Sourcing and GMP Supply for ACC

Overview

Mitotane is a specialty adrenolytic agent for adrenocortical carcinoma, a rare orphan indication with limited global supply. Because only a handful of manufacturers produce it and demand is steady, reliable sourcing sits at the center of patient access. Buyers need qualified GMP suppliers, confirmed registration and planned lead times to avoid stockouts that could interrupt long-term therapy. The 500 mg tablet supports flexible divided dosing, which matters when levels must be titrated carefully under specialist supervision and adjusted as the patient's tolerance and plasma concentration evolve.

How It Works

Mitotane selectively concentrates in the adrenal cortex, where it suppresses corticosteroid synthesis and exerts a direct cytotoxic effect on adrenocortical tumor cells. By blunting the gland's hormone output and acting on the tumor tissue itself, it reduces the hormonal drive that often fuels adrenocortical carcinoma while controlled plasma levels are maintained. The drug's adrenal-specific uptake is what gives it a role distinct from generic chemotherapy in this rare tumor type.

Indications

• Adjuvant treatment of adrenocortical carcinoma after surgery
• Advanced or metastatic adrenocortical carcinoma
• Used with steroid cover and plasma-level monitoring

Dosage & Administration

Initiate at 1 to 3 g per day in two to four divided doses, then titrate toward 3 to 6 g per day for advanced disease as tolerated. The 500 mg tablet allows stepwise increases, with plasma mitotane targeted near 14 to 20 mg per liter. Because adrenal function is suppressed, glucocorticoid replacement is usually needed alongside therapy, and the divided schedule helps smooth the gastrointestinal tolerance during the long titration period.

Storage & Sourcing

Store below 30°C in a dry place. Sourced from a limited set of GMP manufacturers, including TLP and BMS partner lines; confirm the certificate of analysis and local registration, and plan minimum order quantity and lead time for continuity. No dedicated cold chain is required, but batches must stay traceable so any quality or pharmacovigilance signal can be linked back to a specific lot without delay.

FAQ

Q: Why is sourcing mitotane challenging?

A: It is an orphan drug with few manufacturers and steady demand, so buyers need qualified GMP suppliers, confirmed registration and planned lead times to avoid stockouts.

Q: How is dosing monitored?

A: Plasma mitotane is measured and kept near 14 to 20 mg per liter; because adrenal function is suppressed, steroid replacement is usually needed alongside.

Q: What formulation helps titration?

A: The 500 mg tablet allows flexible divided dosing and stepwise increases from 1 to 3 g toward higher maintenance levels under supervision.

Q: What supply conditions keep access stable?

A: Work with qualified GMP suppliers, confirm registration, and plan minimum order quantity and lead time so refills are never interrupted for this long-term therapy.